As a university we seek to generate and apply new knowledge in order to transform society.
entrepreneurship and partnership working with industry are critical components
of this endeavour.
- The SLMS Knowledge Transfer and Enterprise Board seeks to support these activities, working through UCL Enterprise
Each Faculty has a Vice-Dean (Enterprise) who is responsible for developing faculty strategy and operational planning in the area of knowledge transfer and enterprise. They work with the KT Champions and the SLMS Knowledge Transfer and Enterprise Board to enthuse and engage both SLMS academics and external partners in knowledge transfer and entrepreneurial activity.
Our Knowledge Transfer and Enterprise Champions are
appointed to promote Knowledge Transfer within UCL and make it easier for
academics to receive recognition for their work. The seven KT&E champions
working within our four faculties also aim to create inter-departmental links
throughout the university, working with champions outside the School of Life
and Medical Sciences.
- Read more about our KT champions on the UCL Enterprise pages.
The UCL Visiting Professors Scheme aims to bring a greater translational perspective to ongoing academic research within the university by:
- Facilitating inter-department links between functions, with particular focus on clinical and biological departments with chemistry;
- Enhancing the quality and breadth of medicinal chemistry / drug discovery courses at undergraduate and post graduate level
- Increasing academic – industry research collaborations The scheme welcomes experienced individuals from industry to work within UCL and supports UCL academics who wish to be seconded into industry for a period of time.
Professor Veronique Birault
Dr Birault is a Director at GSK and a GSK Visiting Professor at UCL in the Faculty of Medical Sciences in the Division of Infection and Immunity. With fourteen years of pharmaceutical drug discovery and development experience, she has developed extensive skills leading multidisciplinary teams and successful industry/academia partnerships. At UCL, her focus is to bring her translational science expertise to bear and enable collaborative projects dedicated to therapeutic intervention.
Professor Rick Cousins
Rick is a Research Director in new innovative science incubation team within the Alternative Discovery & Development organisation in GSK R&D at Stevenage and also exploring opportunities for drug discovery in diseases of the inner ear.
Rick was a Research Director and Alliance & Project Leader in Centre of Excellence for External Drug Discovery (CEEDD) from 2006 to 2013 supporting the GSK alliances with Epix Pharmaceuticals, Galapagos Pharmaceuticals, Neurosearch, Chroma Therapeutics & Ranbaxy Drug Discovery Group and led the alliance with Peptidream Inc., Prosensa Therapeutics & the Max Planck Institute. The CEEDD group was disbanded in April 2013.
Rick joined GSK medicinal chemistry at Greenford in 1989, after completing chemistry po
Specialties: Medicinal chemistry, drug discovery, alliance leadership & management, externalisation of pharma R&Dst-doctoral & PhD studies at University of London, and held roles of increasing responsibility, ultimately as a group leader & program leader. Rick has worked or led programs at all stages of drug discovery including HTS, lead generation, lead optimisation and clinical candidate selection on a wide variety of targets for many therapeutic areas including anti-virals, anti-fungals, cardiovascular, respiratory, inflammation, neurology and metabolism delivering clinical candidate molecules in many of these therapeutic areas.
Professor Philip Oliver
Philip is currently Director of Partnering and Strategy at MedImmune, AZ’s global biologics research and development arm. Philip is a highly experienced pharmaceutical industry senior executive with 25 years’ experience in small and large molecule drug development and in business development and licensing. Philip also has 8 years of experience in his continuing role as Entrepreneur in Residence at Cambridge University. He has worked extensively on a previous Entrepreneur in Residence programme at UCL, and has brokered over 60 collaboration and partnership deals - many of these between industry and academia
He brings substantial expertise to UCL as a Visiting Professor and is engaging with UCL academics with the view to support and help develop our in-house expertise in undertaking translational (industry-engaged) research, critically assessing research plans with commercial applicability in mind, and cultivating an understanding of how to engage with industry partners for the development of essential new therapeutics
Additionally, Philip sits on the SLMS Translational Research Office internal UCL Confidence in Concept funding panel.
The aims of the TRO are to enhance the translational culture within UCL and to facilitate the translation of UCL’s basic and clinical research into therapies, techniques and medical products with therapeutic value. These aims are achieved through interacting with investigators, identifying translatable opportunities, advising on project progression strategy and accessing suitable funding. The TRO also provides project management expertise to steer programmes towards practical endpoints.
We are able to link investigators to the necessary resources (either internal or external) for projects at all phases - discovery, preclinical or clinical.
- UCL’s Industrial Partnership Group (IPG) provides dedicated support to faculties and departments across UCL SLMS and UCLPartners to identify, develop and manage long-term relationships with companies within the healthcare sector.
- UCL Advances is the centre for entrepreneurship at UCL. It offers training, networking and business support for staff, students and external entrepreneurs to encourage and enable new enterprises to get going.
- UCL Business assists
the technology development process, from consultancy through to collaborative
research, IP licensing and the creation of spinout companies and joint ventures
to maximise the commercial potential of new discoveries, materials and
- UCL Consultants offers bespoke consultancy services from UCL academics to companies and organisations ranging from the small to the very large.
Building on a history of increasing collaboration between UCLPartners, King’s Health Partners, Imperial College Academic Health Science Centre, Oxford and Cambridge, MedCity has been established in partnership with the Greater London Authority (GLA) to provide a vehicle to realise that ambition, ensuring London and the Greater South East become the a global hub for the development of novel therapeutics, devices and diagnostics to address medical need.
UCL has remarkable capability across 5 therapeutic innovation networks, reflecting major therapeutic modalities and diagnostic innovation (imaging, genomics, and molecular pathology).
For details of UCL's engagement with MedCity visit the UCL@MedCity website.
Follow the links for where to find help and support if your primary employer is:
If you are employed by another Trust please speak to the UCLB Business Manager for the UCL academic department you are affiliated with in the first instance. They will be able to connect you to the correct support organisation.
IMPACT studentships support collaborative partnerships between a UCL investigator and external organizations. They allow new partnerships to be established with industrial or enterprise partners, new opportunities for knowledge transfer with external organizations, or support and extend existing partnerships. In recognition of the value of such external partnerships in enterprise and knowledge transfer, UCL makes a significant contribution to the cost of the studentship so that the external partner needs to provide only part of the total funds required.
Studentship costs must be included in the annual planning cycle as they involve a financial commitment from your Institute / Division. For this reason potential applications must be discussed with your Institute or Division Manager or Director as early as possible in the process, as budgets are prepared in late Autumn/January of each year for the following academic year.
The Vice-Deans, Enterprise, will evaluate the academic merits of individual cases, but only your Institute or Division can provide the financial authority for a student to progress. Letters of award will be issued by SLMS Finance once all financial approvals have been secured.
Applications are accepted for IMPACT PhD studentships in each Faculty on a rolling basis. To be considered for an IMPACT studentship, a UCL investigator must identify an external partner and project that fulfills the criteria set out below. The external partner must be willing to commit appropriate supervisory or project support plus a financial commitment as outlined at http://www.ucl.ac.uk/slms/enterprise/funding towards the cost of a three-year PhD. If approved, UCL will then provide the additional funding required. Awards may be used to support 4 year PhDs, where the additional year is charged in full to another source.
IMPACT awards cover home/EU fees, stipend (minimum UK Research Council with London weighting), and research costs of £1000/annum. Any additional costs must be charged entirely to the organisational partner. Awards may be used to support UK and EU nationals only.